Intelligent Bio Solutions Completes Its Initial Clinical Cut-Off Trial For FDA 510(k) Submission For U.S. Market Clearance Of Its Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Inc. (Nasdaq: INBS) has successfully completed its initial clinical Cut-off Study, which supports its FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System aimed at detecting codeine. The study involved 40 adults and confirmed findings through liquid chromatography-tandem mass spectrometry analysis. The company has initiated a second phase, including a multi-site Method Comparison and Usability Study expected to be completed by June 2026, alongside an Interference Study anticipated by July 2026.